FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076827145> ?p ?o ?g. }

• W2076827145 endingPage "384" @default.
• W2076827145 startingPage "383" @default.
• W2076827145 abstract "QUESTION: A 50-year-old woman is seen for evaluation of a facial eruption that has been present intermittently for at least 5 years. The process is located on her mid and lower face. She has used the topical corticosteroid creams diflorasone diacetate 0.05% and hydrocortisone valerate 0.2% for a prolonged period.Indeed, she presents crimped empty tubes to us in hopes of refills (figure 1). These preparations provide temporary relief, but the eruption always returns.Figure 1Nearly empty tubes of medium- and high-potency topical steroids presented by patientExamination shows that she has a light complexion and marked erythema and scaling of the lower face, extending up to the cheeks. The lower lids show minor involvement (figure 2). The eruption spares the vermilion border of the lips and the lips themselves.Figure 2Marked erythema and scaling of the patient's lower faceWhat are the diagnosis, differential diagnosis, and treatment of this condition? What role do prescription topical steroids play in this eruption?ANSWER: This patient has steroid-induced perioral dermatitis, a condition marked by perioral or periorbital erythema and scaling with or without papules that characteristically shows a rim of sparing around the vermilion border of the lips. The process usually starts in a perioral distribution with later involvement of the chin, nasolabial folds, and occasionally the eyelids. It occurs mostly in women.The differential diagnosis includes classic perioral dermatitis, rosacea, and acne. Perioral dermatitis can begin by itself and is seen mostly in women aged 15 to 50 years,1 although it also may rarely affect prepubertal children of both sexes.2 Perioral dermatitis can become steroid-induced perioral dermatitis after prolonged use of topical corticosteroids on the face. Steroid-induced perioral dermatitis is differentiated from common perioral dermatitis by history and clinical behavior. Patients with rosacea and acne can also develop steroid rosacea, steroid acne, or the red-face syndrome after corticosteroid abuse.3 Steroid-induced facial dermatoses tend to have more erythema, inflammation, and scaling than their noniatrogenic counterparts.Mid- or high-potency topical corticosteroids are known to exacerbate perioral dermatitis, acne, and rosacea. They often initiate a cycle of temporary relief and increasingly severe flare-ups on attempt to stop the medicine. This has been described as an “addiction” of the skin to the steroid, requiring increasingly larger and more frequent applications of steroid creams to bring relief.4 Although temporarily reducing the inflammatory reaction, the steroid may increase the overgrowth of the bacteria through local immunosuppression.We have observed that patients with steroid-induced perioral dermatitis often present with vigorously squeezed tubes of corticosteroids that they have used for many months to years. These patients have tried to extract as much of the precious cream as possible to counter the latest flare of the dermatitis. Thus, we term this presentation the “tortured tube” sign.Treatment involves cessation of the topical steroid. Often this regimen initially results in moderate to severe flare-ups of the eruption. The administration of tetracycline, 500 mg by mouth twice a day, and cold tap water compresses will help to alleviate the inflammation. The lesions typically resolve after a few weeks, but occasionally may last as long as 6 months. To ensure therapeutic success, the physician must educate the patient about the course of the disease and the need to discontinue the use of topical corticosteroids.Prevention is more important than cure. Physicians should never prescribe mid- to high-potency topical corticosteroids for facial use without clear oral and written instructions that limit the time of application to no more than 1 to 2 weeks. Even weaker corticosteroid creams have been implicated in initiating facial disorders. Refills of these medicaments should not be given over the phone. A 15-gram tube of a steroid cream may last a patient 6 to 12 months when used only on the face and is sufficient to cause cutaneous addiction with the development of uncomfortable and unsightly dermatoses.In this case, on follow-up several months later, the patient's rash had resolved (figure 3).Figure 3Resolution of the patient's rash several months after abstaining from steroid use" @default.
• W2076827145 created "2016-06-24" @default.
• W2076827145 creator A5038348818 @default.
• W2076827145 creator A5060446918 @default.
• W2076827145 date "2001-06-01" @default.
• W2076827145 modified "2023-09-27" @default.
• W2076827145 title "Tortured tube sign" @default.
• W2076827145 cites W182697229 @default.
• W2076827145 cites W2091984028 @default.
• W2076827145 cites W2141108768 @default.
• W2076827145 doi "https://doi.org/10.1136/ewjm.174.6.383" @default.
• W2076827145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1071421" @default.
• W2076827145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11380999" @default.
• W2076827145 hasPublicationYear "2001" @default.
• W2076827145 type Work @default.
• W2076827145 sameAs 2076827145 @default.
• W2076827145 citedByCount "4" @default.
• W2076827145 countsByYear W20768271452014 @default.
• W2076827145 countsByYear W20768271452019 @default.
• W2076827145 crossrefType "journal-article" @default.
• W2076827145 hasAuthorship W2076827145A5038348818 @default.
• W2076827145 hasAuthorship W2076827145A5060446918 @default.
• W2076827145 hasBestOaLocation W20768271452 @default.
• W2076827145 hasConcept C134306372 @default.
• W2076827145 hasConcept C139676723 @default.
• W2076827145 hasConcept C159985019 @default.
• W2076827145 hasConcept C192562407 @default.
• W2076827145 hasConcept C2777551473 @default.
• W2076827145 hasConcept C33923547 @default.
• W2076827145 hasConcept C41008148 @default.
• W2076827145 hasConceptScore W2076827145C134306372 @default.
• W2076827145 hasConceptScore W2076827145C139676723 @default.
• W2076827145 hasConceptScore W2076827145C159985019 @default.
• W2076827145 hasConceptScore W2076827145C192562407 @default.
• W2076827145 hasConceptScore W2076827145C2777551473 @default.
• W2076827145 hasConceptScore W2076827145C33923547 @default.
• W2076827145 hasConceptScore W2076827145C41008148 @default.
• W2076827145 hasIssue "6" @default.
• W2076827145 hasLocation W20768271451 @default.
• W2076827145 hasLocation W20768271452 @default.
• W2076827145 hasLocation W20768271453 @default.
• W2076827145 hasOpenAccess W2076827145 @default.
• W2076827145 hasPrimaryLocation W20768271451 @default.
• W2076827145 hasRelatedWork W1979026147 @default.
• W2076827145 hasRelatedWork W2130043461 @default.
• W2076827145 hasRelatedWork W2145845399 @default.
• W2076827145 hasRelatedWork W2350741829 @default.
• W2076827145 hasRelatedWork W2358668433 @default.
• W2076827145 hasRelatedWork W2376932109 @default.
• W2076827145 hasRelatedWork W2382290278 @default.
• W2076827145 hasRelatedWork W2390279801 @default.
• W2076827145 hasRelatedWork W2748952813 @default.
• W2076827145 hasRelatedWork W2899084033 @default.
• W2076827145 hasVolume "174" @default.
• W2076827145 isParatext "false" @default.
• W2076827145 isRetracted "false" @default.
• W2076827145 magId "2076827145" @default.
• W2076827145 workType "article" @default.